FABP5 and posterior cortical atrophy: FABP5 inhibition provides a synergistic effect in combination with chemotherapy [136], and the reported dependence of PTEN loss-driven PCa [137] on this enzyme encourages the evaluation of this therapeutic strategy in a stratified population.